Niki BioSolutions, Inc.（NIKI）财务数据NIKINiki BioSolutions, Inc.

In the context of the broader market, NIKI competes directly with industry leaders such as CNSY and PULM. With a market capitalization of $4.70M, it holds a significant position in the sector. When comparing efficiency, NIKI's gross margin of N/A stands against CNSY's 100.00% and PULM's N/A. Such benchmarking helps identify whether Aptorum Group Ltd is trading at a premium or discount relative to its financial performance.

Niki Biosolutions has a current ratio of 0.56, indicating it does not have enough current assets to cover its current liabilities. The PE ratio is negative at -1.35, and the company has reported a net income loss of $613,995 in Q3 2025.